Items where Subject is "diseases & disorders > cancer > drugs and therapies > Immunotherapy"

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Authors | Item Type
Jump to: B | C | D | F | G | J | M | R | S | T | V
Number of items at this level: 15.

B

Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., Vonderheide, R. H., Pittet, M. J., Jain, R. K., Zou, W., Howcroft, T. K., Woodhouse, E. C., Weinberg, R. A., Krummel, M. F. (May 2018) Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med, 24 (5). pp. 541-550. ISSN 1078-8956

Burgess, M. A., Bolejack, V., Schuetze, S., Van Tine, B. A., Attia, S., Riedel, R. F., Hu, J. S., Davis, L. E., Okuno, S. H., Priebat, D. A., Movva, S., Reed, D. R., D'Angelo, S. P., Lazar, A. J., Keung, E. Z. Y., Reinke, D. K., Baker, L. H., Maki, R. G., Patel, S., Tawbi, H. A. H. (May 2019) Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts. In: Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO).

C

Connell, C. M., Raby, S., Beh, I., Flint, T., Williams, E., Fearon, D. T., Jodrell, D. I., Janowitz, T. (July 2017) Cancer immunotherapy trial registrations increase exponentially but chronic immunosuppressive glucocorticoid therapy may compromise outcomes. Ann Oncol, 28 (7). pp. 1678-1679. ISSN 0923-7534

Connell, C. M., Raby, S. E. M., Beh, I., Flint, T. R., Williams, E. H., Fearon, D. T., Jodrell, D. I., Janowitz, T. (January 2018) Cancer Immunotherapy Trials Underutilize Immune Response Monitoring. Oncologist, 23 (1). pp. 116-117. ISSN 1083-7159

D

Dancsok, A. R., Setsu, N., Gao, D., Blay, J. Y., Thomas, D., Maki, R. G., Nielsen, T. O., Demicco, E. G. (July 2019) Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas. Mod Pathol. ISSN 0893-3952

F

Fearon, D. T. (March 2017) Immune-Suppressing Cellular Elements of the Tumor Microenvironment. Annual Review of Cancer Biology, 1 (1). pp. 241-255. ISSN 2472-3428

Fessas, P., Lee, H., Ikemizu, S., Janowitz, T. (April 2017) A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab. Semin Oncol, 44 (2). pp. 136-140. ISSN 0093-7754

Flint, T. R., Jones, J. O., Ferrer, M., Colucci, F., Janowitz, T. (March 2018) A comparative analysis of immune privilege in pregnancy and cancer in the context of checkpoint blockade immunotherapy. Semin Oncol. ISSN 0093-7754

G

Ghosh, D., Venkataramani, P., Nandi, S., Bhattacharjee, S. (January 2019) CRISPR-Cas9 a boon or bane: the bumpy road ahead to cancer therapeutics. Cancer Cell Int, 19. p. 12. ISSN 1475-2867 (Print)1475-2867

J

Janowitz, T., Welsh, S. J., Zaki, K., Mulders, P., Eisen, T. (August 2013) Adjuvant therapy in renal cell carcinoma-past, present, and future. Semin Oncol, 40 (4). pp. 482-91. ISSN 0093-7754

M

Maiorino, L., Egeblad, M. (August 2019) Tumours pick the path to cancer inflammation. Nat Cell Biol. ISSN 1465-7392

R

Rozenblit, M., Hendrickx, W., Heguy, A., Chiriboga, L., Loomis, C., Ray, K., Darvishian, F., Egeblad, M., Demaria, S., Marincola, F. M., Bedognetti, D., Adams, S. (June 2019) Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod. Sci Rep, 9 (1). p. 8572. ISSN 2045-2322

S

Stacchiotti, S., Mir, O., Le Cesne, A., Vincenzi, B., Fedenko, A., Maki, R. G., Somaiah, N., Patel, S., Brahmi, M., Blay, J. Y., Boye, K., Sundby Hall, K., Gelderblom, H., Hindi, N., Martin-Broto, J., Kosela, H., Rutkowski, P., Italiano, A., Duffaud, F., Kobayashi, E., Casali, P. G., Provenzano, S., Kawai, A. (January 2018) Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. Oncologist, 23 (1). pp. 62-70. ISSN 1083-7159

T

Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T. H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., Ziv, E., Culhane, A. C., Paull, E. O., Sivakumar, I. K. A., Gentles, A. J., Malhotra, R., Farshidfar, F., Colaprico, A., Parker, J. S., Mose, L. E., Vo, N. S., Liu, J., Liu, Y., Rader, J., Dhankani, V., Reynolds, S. M., Bowlby, R., Califano, A., Cherniack, A. D., Anastassiou, D., Bedognetti, D., Rao, A., Chen, K., Krasnitz, A., Hu, H., Malta, T. M., Noushmehr, H., Pedamallu, C. S., Bullman, S., Ojesina, A. I., Lamb, A., Zhou, W., Shen, H., Choueiri, T. K., Weinstein, J. N., Guinney, J., Saltz, J., Holt, R. A., Rabkin, C. E., Lazar, A. J., Serody, J. S., Demicco, E. G., Disis, M. L., Vincent, B. G., Shmulevich, L. (April 2018) The Immune Landscape of Cancer. Immunity, 48 (4). pp. 812-830. ISSN 1074-7613

V

Verspoor, F. G. M., Mastboom, M. J. L., Hannink, G., Maki, R. G., Wagner, A., Bompas, E., Desai, J., Italiano, A., Seddon, B. M., van der Graaf, W. T. A., Blay, J. Y., Brahmi, M., Eberst, L., Stacchiotti, S., Mir, O., van de Sande, M. A. J., Gelderblom, H., Cassier, P. A. (October 2019) Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor. Sci Rep, 9 (1). p. 14551. ISSN 2045-2322

This list was generated on Tue Dec 10 14:21:20 2019 EST.
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving